Latest Interleukin Genetics (ILIU) Headlines
Post# of 4
Posted On: 03/10/2014 6:03:55 AM
Latest Interleukin Genetics (ILIU) Headlines
PhotoMedex Appoints Trevor S. Harris to Its Board of Directors
Business Wire - Tue Mar 04, 7:30AM CST
PhotoMedex, Inc. (NasdaqGS and TASE: PHMD) announces the appointment of Trevor S. Harris, Ph.D., CA (SA) to the Company's board of directors, returning the board's size to eight members. Effective April 1, 2014, Dr. Harris will also serve as chairman of the Company's audit committee. He replaces Dr. Nahum Melumad, who passed away on January 15, 2014.
Interleukin Genetics Introduces PerioPredict(TM)
Business Wire - Mon Nov 25, 6:00AM CST
Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the introduction of PerioPredict(TM), the Company's new, next-generation version of the PST(R) genetic risk test for periodontal disease. PerioPredict(TM) will be broadly available beginning January 2014.
Interleukin Genetics Reports Third Quarter 2013 Financial Results
Business Wire - Thu Nov 14, 3:18PM CST
Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for the third quarter ended September 30, 2013.
Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2013 Results
Business Wire - Wed Nov 06, 3:15PM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Thursday, November 14, 2013 at 4:30 p.m. (EST) to provide a corporate update and discuss the Company's third quarter results.
Interleukin Genetics Reports Second Quarter 2013 Financial Results
Business Wire - Wed Aug 14, 3:20PM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for the second quarter ended June 30, 2013.
Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2013 Results
Business Wire - Tue Aug 06, 3:15PM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and Webcast on Wednesday, August 14, 2013 at 4:30 p.m. (ET) to provide a corporate update and discuss the Company's second quarter results.
Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Study Published in Journal of Dental Research Demonstrates Value of Genetics in Preventing Periodontal Disease
Business Wire - Mon Jun 10, 10:32AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the online publication of the research study "Patient Stratification for Preventive Dental Care" in Journal of Dental Research. The study provides new insights into the prevention of periodontitis (gum disease) and the opportunity for significant advancement in the delivery of personalized, preventive dental care. Periodontitis affects 47 percent of the adult population.
Interleukin Genetics to Discuss Corporate Update and First Quarter Results
Business Wire - Thu May 23, 3:05PM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) will host a conference call and Webcast today at 4:30 p.m. (EDT) to provide a corporate update and discuss the Company's first quarter results.
Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2013 Results
Business Wire - Mon May 20, 11:00AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and Webcast on Thursday, May 23, 2013 at 4:30 p.m. (EST) to provide a corporate update and discuss the Company's first quarter results.
Interleukin Genetics Announces $12 Million Private Placement
Business Wire - Mon May 20, 6:55AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it has raised $12.0 million in gross proceeds through a private placement of its securities to accredited investors. Interleukin sold an aggregate of 43,715,847 shares of its common stock at a price of $0.2745 per share and issued warrants to purchase an aggregate of 32,786,885 shares of common stock at an exercise price of $0.2745 per share to the investors.
PST Manuscript Submitted, Awaiting Publication Acceptance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 17, 7:04PM CDT
PST Manuscript Submitted, Awaiting Publication Acceptance
Interleukin Genetics and University of North Carolina Publish Genetic Factors Predictive of Progression of Knee Osteoarthritis
Business Wire - Wed May 08, 7:35AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today the online publication in Osteoarthritis and Cartilage of a study with investigators at the Thurston Arthritis Research Center of the University of North Carolina entitled, "IL-1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort."
Interleukin Genetics Reports Fourth Quarter and Year End 2012 Financial Results
Business Wire - Thu Mar 28, 3:20PM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2012.
Interleukin Genetics, Inc. Announces Conference Call to Discuss Fourth Quarter 2012 Results
Business Wire - Thu Mar 21, 3:20PM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and Webcast on Thursday, March 28, 2013 at 4:30 p.m. (EST) to discuss the Company's fourth quarter and 2012 year end results.
Initial Agreement With Renaissance Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 04, 4:11PM CST
Interleukin Genetics (OTC Markets:ILIU) penned an initial agreement with Renaissance Health Service Corp (RHSC) relative to reimbursement of the company's PST test.
Interleukin Genetics Appoints Scott Snyder as Chief Marketing Officer
Business Wire - Thu Jan 03, 3:10PM CST
Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the appointment of Scott Snyder as Chief Marketing Officer. In this role, Scott will spearhead the launch of the company's proprietary PST(R) genetic risk panel to guide more effective dental preventive care. Scott will have responsibility for marketing Interleukin's professional healthcare tests, including PST(R) and a proprietary test for osteoarthritis progression, and for the Inherent Health(R) brand of health and wellness genetic tests within consumer channels.
PhotoMedex Appoints Trevor S. Harris to Its Board of Directors
Business Wire - Tue Mar 04, 7:30AM CST
PhotoMedex, Inc. (NasdaqGS and TASE: PHMD) announces the appointment of Trevor S. Harris, Ph.D., CA (SA) to the Company's board of directors, returning the board's size to eight members. Effective April 1, 2014, Dr. Harris will also serve as chairman of the Company's audit committee. He replaces Dr. Nahum Melumad, who passed away on January 15, 2014.
Interleukin Genetics Introduces PerioPredict(TM)
Business Wire - Mon Nov 25, 6:00AM CST
Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the introduction of PerioPredict(TM), the Company's new, next-generation version of the PST(R) genetic risk test for periodontal disease. PerioPredict(TM) will be broadly available beginning January 2014.
Interleukin Genetics Reports Third Quarter 2013 Financial Results
Business Wire - Thu Nov 14, 3:18PM CST
Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for the third quarter ended September 30, 2013.
Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2013 Results
Business Wire - Wed Nov 06, 3:15PM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Thursday, November 14, 2013 at 4:30 p.m. (EST) to provide a corporate update and discuss the Company's third quarter results.
Interleukin Genetics Reports Second Quarter 2013 Financial Results
Business Wire - Wed Aug 14, 3:20PM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for the second quarter ended June 30, 2013.
Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2013 Results
Business Wire - Tue Aug 06, 3:15PM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and Webcast on Wednesday, August 14, 2013 at 4:30 p.m. (ET) to provide a corporate update and discuss the Company's second quarter results.
Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Study Published in Journal of Dental Research Demonstrates Value of Genetics in Preventing Periodontal Disease
Business Wire - Mon Jun 10, 10:32AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the online publication of the research study "Patient Stratification for Preventive Dental Care" in Journal of Dental Research. The study provides new insights into the prevention of periodontitis (gum disease) and the opportunity for significant advancement in the delivery of personalized, preventive dental care. Periodontitis affects 47 percent of the adult population.
Interleukin Genetics to Discuss Corporate Update and First Quarter Results
Business Wire - Thu May 23, 3:05PM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) will host a conference call and Webcast today at 4:30 p.m. (EDT) to provide a corporate update and discuss the Company's first quarter results.
Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2013 Results
Business Wire - Mon May 20, 11:00AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and Webcast on Thursday, May 23, 2013 at 4:30 p.m. (EST) to provide a corporate update and discuss the Company's first quarter results.
Interleukin Genetics Announces $12 Million Private Placement
Business Wire - Mon May 20, 6:55AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it has raised $12.0 million in gross proceeds through a private placement of its securities to accredited investors. Interleukin sold an aggregate of 43,715,847 shares of its common stock at a price of $0.2745 per share and issued warrants to purchase an aggregate of 32,786,885 shares of common stock at an exercise price of $0.2745 per share to the investors.
PST Manuscript Submitted, Awaiting Publication Acceptance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 17, 7:04PM CDT
PST Manuscript Submitted, Awaiting Publication Acceptance
Interleukin Genetics and University of North Carolina Publish Genetic Factors Predictive of Progression of Knee Osteoarthritis
Business Wire - Wed May 08, 7:35AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today the online publication in Osteoarthritis and Cartilage of a study with investigators at the Thurston Arthritis Research Center of the University of North Carolina entitled, "IL-1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort."
Interleukin Genetics Reports Fourth Quarter and Year End 2012 Financial Results
Business Wire - Thu Mar 28, 3:20PM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2012.
Interleukin Genetics, Inc. Announces Conference Call to Discuss Fourth Quarter 2012 Results
Business Wire - Thu Mar 21, 3:20PM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and Webcast on Thursday, March 28, 2013 at 4:30 p.m. (EST) to discuss the Company's fourth quarter and 2012 year end results.
Initial Agreement With Renaissance Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 04, 4:11PM CST
Interleukin Genetics (OTC Markets:ILIU) penned an initial agreement with Renaissance Health Service Corp (RHSC) relative to reimbursement of the company's PST test.
Interleukin Genetics Appoints Scott Snyder as Chief Marketing Officer
Business Wire - Thu Jan 03, 3:10PM CST
Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the appointment of Scott Snyder as Chief Marketing Officer. In this role, Scott will spearhead the launch of the company's proprietary PST(R) genetic risk panel to guide more effective dental preventive care. Scott will have responsibility for marketing Interleukin's professional healthcare tests, including PST(R) and a proprietary test for osteoarthritis progression, and for the Inherent Health(R) brand of health and wellness genetic tests within consumer channels.
(0)
(0)Interleukin Genetics (ILIU) Stock Research Links
Scroll down for more posts ▼